Celldex Therapeutics (NASDAQ:CLDX) Receives "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX - Free Report) in a research report released on Thursday morning,Benzinga reports. They currently have a $67.00 target price on the biopharmaceutical company's stock.

Other equities analysts have also issued reports about the company. Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research report on Monday, September 30th. They set a "neutral" rating and a $45.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. Citigroup assumed coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $70.00 price objective for the company. Finally, Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $62.25.

Celldex Therapeutics Trading Up 2.1 %

Shares of CLDX traded up $0.52 during trading hours on Thursday, reaching $25.79. 867,531 shares of the stock traded hands, compared to its average volume of 885,965. Celldex Therapeutics has a 52 week low of $22.93 and a 52 week high of $53.18. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -10.04 and a beta of 1.57. The stock has a fifty day simple moving average of $26.12 and a 200 day simple moving average of $32.76.

Insider Transactions at Celldex Therapeutics

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.80% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its holdings in shares of Celldex Therapeutics by 14.5% in the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock worth $314,190,000 after purchasing an additional 1,167,659 shares during the period. Bellevue Group AG grew its position in Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company's stock worth $104,404,000 after buying an additional 100,000 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock worth $71,725,000 after acquiring an additional 654,194 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Celldex Therapeutics by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company's stock valued at $52,372,000 after acquiring an additional 6,557 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company's stock valued at $50,995,000 after acquiring an additional 479,068 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.